Jonathon Vallejo

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 13

Top Topics

Acute Myeloid Leukemia

Newly Diagnosed

Drug Administration

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Jonathon Vallejo, Harpreet Singh, Erin Larkins, Nicole Drezner, Biagio Ricciuti, Pallavi Mishra-Kalyani, Shenghui Tang, Julia A Beaver, Mark M Awad
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials. The oncologist 29 (5) (2024)
Jonathon Vallejo, Harpreet Singh, Erin Larkins, Nicole Drezner, Biagio Ricciuti, Pallavi Mishra-Kalyani, Shenghui Tang, Julia A Beaver, Mark M Awad
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials. The oncologist 29 (5) (2024)
Gulsum E Pamuk, Edwin C Y Chow, Alexei C Ionan, Haiyan Chen, Shwu-Luan Lee, Vicky Hsu, Manuela Grimstein, Nan Zheng, Jielin Sun, Rosane Charlab, Brenda J Gehrke, Jonathon Vallejo, Lori A Ehrlich, R Angelo de Claro, Marc R Theoret
FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Jonathon Vallejo, Harpreet Singh, Erin Larkins, Nicole Drezner, Biagio Ricciuti, Pallavi Mishra-Kalyani, Shenghui Tang, Julia A Beaver, Mark M Awad
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials. The oncologist 29 (5) (2024)
Jonathon Vallejo, Harpreet Singh, Erin Larkins, Nicole Drezner, Biagio Ricciuti, Pallavi Mishra-Kalyani, Shenghui Tang, Julia A Beaver, Mark M Awad
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials. The oncologist 29 (5) (2024)
Jonathon Vallejo, Harpreet Singh, Erin Larkins, Nicole Drezner, Biagio Ricciuti, Pallavi Mishra-Kalyani, Shenghui Tang, Julia A Beaver, Mark M Awad
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials. The oncologist (2024)
Lisa R Rodriguez, Nicole J Gormley, Ruixiao Lu, Anup K Amatya, George D Demetri, Keith T Flaherty, Ruben A Mesa, Richard Pazdur, Mikkael A Sekeres, Minghua Shan, Steven Snapinn, Marc R Theoret, Rukiya Umoja, Jonathon Vallejo, Nicholas J H Warren, Qing Xu, Kenneth C Anderson
Improving Collection and Analysis of Overall Survival Data. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Ashley C Woods, Kelly J Norsworthy, Xin Wang, Jonathon Vallejo, Edwin C Y Chow, Ruo-Jing Li, Jielin Sun, Rosane Charlab, Xiling Jiang, Richard Pazdur, Marc R Theoret, R Angelo de Claro
FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Donna Przepiorka, Robert Q Le, Alexei Ionan, Ruo-Jing Li, Ying-Hong Wang, Ramadevi Gudi, Soumya Mitra, Jonathon Vallejo, Olanrewaju O Okusanya, Lian Ma, Yuching Yang, Paresma Patel, Djelila Mezaache, Rakhi Shah, Anamitro Banerjee, Sherita McLamore, Adam N Maung, Kirsten B Goldberg, Richard Pazdur, Marc R Theoret, R Angelo De Claro
FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (12) (2022)
Nina Kim, Kelly J Norsworthy, Sriram Subramaniam, Haiyan Chen, Michael L Manning, Eliford Kitabi, Justin Earp, Lori A Ehrlich, Olanrewaju O Okusanya, Jonathon Vallejo, Brenda J Gehrke, R Angelo de Claro, Richard Pazdur
FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (16) (2022)
Emily Y Jen, Xin Wang, Meng Li, Hongshan Li, Shwu-Luan Lee, Nina Ni, Donna Przepiorka, Jonathon Vallejo, Ruby Leong, Lian Ma, Brenda J Gehrke, Sherita McLamore, Marc R Theoret, R Angelo de Claro
FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (14) (2022)
Jeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, Joyce Cheng, Amal Ayyoub, Jiang Liu, Rachel Hudson, Rajeshwari Sridhara, Gwynn Ison, Laleh Amiri-Kordestani, Shenghui Tang, Thomas Gwise, Atiqur Rahman, Richard Pazdur, Marc R Theoret
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (30) (2022)
Kelly J Norsworthy, Xin Gao, Chia-Wen Ko, E Dianne Pulte, Jiaxi Zhou, Yutao Gong, Yuan Li Shen, Jonathon Vallejo, Thomas E Gwise, Rajeshwari Sridhara, Albert B Deisseroth, Ann T Farrell, R Angelo de Claro, Gideon M Blumenthal, Richard Pazdur
Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)